Shareholders that lost money on Iovance Biotherapeutics, Inc.(IOVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading statements about its growth potential while concealing adverse facts regarding its ability to meet demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].